Navigation Links
Alimera Sciences' Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
Date:4/8/2009

ATLANTA, April 8 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that an independent Data Safety Monitoring Board (DSMB) has recommended the continuation of two pivotal Phase 3 clinical trials for the use of Iluvien(TM) in the treatment of diabetic macular edema (DME) under the current protocol, without change. The Board completed its final review of the currently available safety and efficacy data prior to the readout in October 2009. A DSMB provides an independent evaluation of all trial data to identify potential safety issues that might warrant modification or early termination of ongoing clinical studies.

These clinical trials, known collectively as the FAME(TM) Study (Fluocinolone Acetonide in Diabetic Macular Edema), consist of two 36-month, doublemasked, randomized, multi-center trials in the U.S., Canada, Europe and India in support of a planned global registration filing. Safety and efficacy will be assessed after 24 months of follow-up, which will occur in October of this year.

"Alimera is pleased that the DSMB recommended the continuation of the FAME Study without change," said Alimera CEO Dan Myers. "We are looking forward to the last patient, last visit for the 24-month readout scheduled in October later this year."

Iluvien is an intravitreal insert being developed for the treatment of DME. DME is a disease of the retina, which affects individuals with diabetes and can lead to severe vision loss and blindness. Each Iluvien insert is designed to provide a sustained therapeutic effect, up to 36 months for the low dose and up to 24 months for the high dose. Iluvien is inserted into the patient's eye with a 25-gauge needle, which allows for a self-sealing wound. This insertion is very similar to an intra
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
2. Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
3. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
4. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
5. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
6. Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
7. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
8. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
9. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
10. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
11. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... MOUNTAIN VIEW, Calif. , May 1, 2015 /PRNewswire/ ... the United States launch of ... an integrated, fast and easy system for exosome collection ... International Society for Extracellular Vesicles ("ISEV") Annual Meeting, April ... , D.C.  Both products are intended for research use ...
(Date:5/1/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/pjbxjd/us_aco_it ... ACO IT Spending Outlook 2018" report to their ... lives covered by ACO would grow at a CAGR ... ACO IT spending has been studied on three main ... spending on services. Our research provides current market estimation ...
(Date:5/1/2015)... May 1, 2015 Braeburn Pharmaceuticals ... current therapeutic focus beyond addiction and pain ... disorders. Braeburn has acquired an implantable, six-month ... risperidone for treatment of schizophrenia from Endo ... global rights to other potential applications of ...
Breaking Medicine Technology:New Products for Exosome Isolation to mRNA Purification 2United States ACO IT Spending Outlook 2014-2018 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 4
(Date:5/2/2015)... (PRWEB) May 03, 2015 As one ... of the prestigious Safety and Health Achievement and Recognition ... honored to be chosen by the Illinois Department of ... has achieved and maintained SHARP certification by the Occupational ... 2006, as Essentra has continued to meet or exceed ...
(Date:5/2/2015)... ProText Kinetic 2 is a set of typography creation ... ProText Kinetic 2 features 40 animation presets that ... . Easily create interactive text videos without having to ... 2. , Using ProText Kinetic is as easy as drag ... in the FCPX timeline. Playback the default animation and ...
(Date:5/2/2015)... East Liverpool, Ohio (PRWEB) May 02, 2015 ... of East Liverpool City Hospital (ELCH) gathered to celebrate ... direction of River Valley Health Partners (RVHP), had zero ... and zero urinary catheter associated infections. ELCH was also ... , The management team at ELCH credited the ...
(Date:5/2/2015)... With the success that Veatch Dental Consulting has had over ... and Alex Shields to the team. With Neida and Alex ... combined experience working with dentists to ensure their success. , ... years. She was certified as dental assistant from Texas ... and showing the importance of oral hygiene to patients, Neida ...
(Date:5/1/2015)... 01, 2015 Jusuru International has been ... successful repositioning of its flagship nutritional supplement, Liquid BioCell™ ... a new name, new logo, new packaging, new products, ... are designed to identify and promote programs that serve ... , “DSA congratulates Jusuru International for their outstanding accomplishments ...
Breaking Medicine News(10 mins):Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2Health News:Veatch Dental Consulting Services Welcomes New Team Members 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5
... April 30 Approximately sixty-five state and local public ... responsibility for confirmatory testing of Human Influenza A H1N1 ... week. Previously, all swine flu specimens had to be ... testing, which identifies specimens to the strain level.The rRT-PCR ...
... Justice grant creates federal-state-local partnership to help fight ... A sweeping $1.1 million U.S. Justice Dept. grant ... prosecution agency to help combat domestic violence and ... State,s Attorney,s Appellate Prosecutor,s office has hired two ...
... the pancreas, invagination of the pancreas into the small ... according to researchers at the Jefferson Pancreas, Biliary and ... Journal of the American College of Surgeons . ... gold standard for studies. , Removing the head of ...
... agreement on principles for Getting Health IT Right under ... Today the Markle Foundation hosts a forum to ... information technology (IT) under the American Recovery and Reinvestment ... will meet with government and policy experts to talk ...
... Golf Car and a Day on the Field of a ... April 30 On Saturday, May 2 nd ... at the Los Angeles Equestrian Center for the 11th Annual ... support of raising funds for cancer research. Fiesta, a ...
... Podcast from Perot Systems on the Role of Information Technology in Improving HealthcarePLANO, Texas, ... Dr. Harry Greenspun, executive vice president and chief, ... Guest: Dr. Nathaniel Hupert, Director of The Preparedness Modeling Unit, ... Centers for Disease Control and Prevention (CDC) and, ...
Cached Medicine News:Health News:Public Health Laboratories To Assume Primary Responsibility for Confirmatory Testing of Swine Flu 2Health News:New Illinois Prosecution Unit Helps Protect Women Against Violence 2Health News:Type of connection procedure after pancreatic surgery influenced rate of pancreatic fistula 2Health News:Meaningful Investment of $19 Billion on Health Information Technology 2Health News:Meaningful Investment of $19 Billion on Health Information Technology 3Health News:Celebrities, Horses, Music and History Will Unite for 2009 'Fiesta of the Spanish Horse' Cancer Research Benefit 2Health News:Looking Forward: The Use of Health IT in Crisis 2Health News:Looking Forward: The Use of Health IT in Crisis 3Health News:Looking Forward: The Use of Health IT in Crisis 4
... Mid-Calf Boot is a shorter and ... designed for second degree ankle sprains, ... protection. The Bledsoe EZ Set Mid-Calf ... motion from 20 degrees of dorsi-flexion ...
... Diabetic Boot features a fully enclosed thick, ... unique auto-molding innersole which embeds into a ... aluminum shelled walking boot. This unique Automold™ ... distribute body weight across the entire bottom ...
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
DarcoGel™ Upper chamber is foam filled, conforms to calf; gel-filled lower chamber molds to the malleoli for a custom fit. Freeze the removable liner for cold therapy. One size. Fits left or ri...
Medicine Products: